NXC680 / Nextgen Biosci - LARVOL DELTA

Nextgen’s idiopathic pulmonary fibrosis treatment, designated as an orphan drug by the US FDA [Google translation] (docdocdoc.co.kr) - "Nextgen Bioscience...announced on the 26th that the U.S. Food and Drug Administration (FDA) has designated 'NXC680', a drug candidate for idiopathic pulmonary fibrosis (IPF), as an Orphan Drug Designation (ODD)....Nextgen plans to apply for an IND (clinical trial protocol) for domestic phase 1 clinical trial of NXC680 in the second quarter of this year, and is planning to accelerate discussions on business development from various angles for global technology transfer of NXC680."

IND • Orphan drug • Idiopathic Pulmonary Fibrosis • Interstitial Lung Disease